Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)

NCT02761070 is registered in ClinicalTrials.gov with Kyorin University as lead sponsor.

NCT NCT02761070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02761070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)
Lead sponsor
Kyorin University
Phase
Phase 3
Overall status
Completed
Start date
July 11, 2016
Completion date
April 17, 2025
Enrollment
146 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, progression, recurrence